Jan 2025
Find us among IMPACT startups at Web Summit Qatar
As a pioneer in transforming autism diagnosis, our work contributes to the UN’s SDG 3: Good Health and Well-being.
BlueSavant AI is participating in the Caelestinus accelerator.
BlueSavant AI Autism Test
A simple blood test, a framework of gene expressions, and machine learning.
Our test can proactively identify autism in children as young as 18 months, before symptoms appear — a screening step that fits into routine childcare. It augments behavioural assessment with precise, data-driven analysis.
How it works
A 1 mL blood sample, read as RNA, scored by machine learning.
1 mL
Blood sample
a single routine draw, no imaging and no behavioural session.
RNA
What we read
gene expression, which shows what is active in the body rather than what is merely inherited.
18 mo
AAP screening age
the American Academy of Pediatrics recommends autism diagnosis at 18 months.
The BlueSavant AI Autism Test is in development and is not FDA-cleared. No diagnostic performance figures are published on this site.
Why it matters
Autism diagnosis has not materially changed in 40 years.
A child showing a developmental disorder today still faces years of waiting.
5 years
is the average age at diagnosis, missing the impact of early intervention.
4 months
of waiting time in two thirds of therapy centres.
15 sessions
of assessment until a diagnosis is confirmed.
$10,000
in healthcare costs incurred before reaching a diagnosis.
Join the priority list
Working on autism diagnosis? We would like to hear from you.
We are speaking with clinicians, researchers, health systems and investors as the test moves toward validation.
Get in touchNews
News & updates
Dec 2024
We are exhibiting in Qatar
We are thrilled to announce our participation in Web Summit Qatar 2025, 23–26 February.
Dec 2024
Boston Entrepreneurs’ Network at Lasell University
AI can put patients one step ahead of disease. At BlueSavant AI, we believe in enabling humanity.